共查询到15条相似文献,搜索用时 62 毫秒
1.
2.
以2-(3-甲酰基-4-异丁氧基一苯基)-4-甲基-噻唑-5-甲酸乙酯为原料,经醛肟脱水、水解制备非布索坦,并对其工艺进行了优化。合成的非布索坦纯度达到99%以上,单个杂质不超过0.1%,总收率达63.31%。优化后的工艺简单易控,产品纯度及收率较高,达到药用标准。 相似文献
3.
4.
5.
6.
7.
8.
9.
10.
异黄酮化合物的“一锅法“合成工艺 总被引:2,自引:0,他引:2
探索不同催化体系下“一锅法”化学合成异黄酮化合物的工艺。以多元酚和取代苯乙酸衍生物为主要原料,不需分离中间产物,“一锅法”合成得到异黄酮终产物。3种催化体系下均可“一锅法”合成异黄酮化合物,产物结构经理化常数和1HNMR谱确证。以三氟化硼乙醚/三氯化磷为催化剂的“一锅法”合成工艺条件温和,收率较高。 相似文献
11.
12.
13.
14.
Xanthine oxidase (XO) is the enzyme responsible for the catabolism of purines and their conversion into uric acid. XO is thus the target for the treatment of hyperuricemia and gout. For more than 50 years the only XO inhibitor drug available on the market was the purine analogue allopurinol. In the last decade there has been a resurgence in the search for new inhibitors of XO, as the activity of XO and hyperuricemia have also been associated with a variety of conditions such as diabetes, hypertension, and other cardiovascular diseases. In recent years the non-purine inhibitor febuxostat was approved in Europe and the USA for the treatment of hyperuricemia. This drug was followed by another XO inhibitor called topiroxostat. This review discusses the molecular structures and activities of the multiple classes of inhibitors that have been developed since the discovery of allopurinol, with a brief review of the molecular interactions between inhibitors and XO active site residues for the most important molecules. The challenges ahead for the discovery of new inhibitors of XO with novel chemical structures are discussed. 相似文献
15.
以丙醛为原料,氯铬酸吡啶(PCC)为氧化剂,乙酸乙酯为溶剂,通过一锅法,在常温常压下合成得到草莓酸,总收率为85.3%。所得产品用IR、1 H NMR等方法进行表征。 相似文献